



CHEMCON
Speciality Chemicals Limited



CIN : L24231GJ1988PLC011652

May 19, 2025

To,
BSE Limited
Listing Compliance & Legal Regulatory
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
Stock Code: 543233

To,
National Stock Exchange of India Limited
Listing & Compliance
Exchange Plaza, Bandra-Kurla Complex,
Bandra East, Mumbai 400 051
Stock Symbol: CHEMCON

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing obligations and Disclosure Requirements), Regulations, 2015, please find enclose herewith the "Investor Presentation" for May 2025.

The aforementioned presentation is also being uploaded on the Company's website at www.cscpl.com.

We request you to take the above on your records.

Thanking you,

Yours faithfully,


For Chemcon Speciality Chemicals Limited

Shahilkumar Kapatel
Company Secretary & Compliance Officer
Membership No.: A52211



Chemcon Speciality Chemicals Limited


Investor Presentation – May 2025



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Chemcon Speciality Chemicals Limited (the “Company”)**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



Q4 & FY25 Performance Highlights



Q4 & FY25 Performance Highlights



“For FY25, we reported profit after tax (PAT) of Rs. 24 crores reflecting a 27% increase compared to previous year. The year witnessed subdued demand across both organic and inorganic segments, largely influenced by global economic uncertainty, lower realizations, and supply chain disruptions. Our key organic chemicals—HMDS, CMIC, and Bromobenzene remained flattish and were affected due to soft demand from pharmaceutical and agrochemical clients.

Despite these headwinds, we witnessed early signs of recovery in demand for some organic chemicals and continued to receive enquiries for our newly launched products, especially those aligned with the import substitution market. These new products are currently undergoing client approvals, and trial dispatches have commenced. We remain optimistic about their commercial potential in the coming quarters.

Our inorganic chemicals business faced volatility throughout the period, impacted by fluctuating crude oil prices, ongoing geopolitical tensions and deferred client dispatches. Resulting in decreased volumes from our inorganic segment. Our upcoming P-10 and P-11 manufacturing units at Manjusar, with commissioning targeted in H1 FY26, respectively. These facilities will support our focus on pharmaceutical applications also aligning with our strategy to de-risk our product portfolio. With ongoing customer engagements and a broadened product pipeline, we are confident in our ability to deliver steady and sustainable growth in the upcoming quarters.”


Mr. Kamal Aggarwal,

Chairman & Managing Director


Financial Highlights




Revenue from Operations (Rs. Cr)




EBITDA (Rs. Cr)




PAT (Rs. Cr)




Geographic-Wise (%)



Business-wise (%)



Sales Volume (MT)




Organic chemicals refers to HMDS, CMIC, Bromobenzene and 2 Bromo whereas Inorganic chemicals refer to Bromides


Export data are inclusive of Deemed Exports

Financial Highlights


Revenue from
Operations (Rs. Cr)




EBITDA (Rs. Cr)




PAT (Rs. Cr)




Geographic-Wise (%)



Business-wise (%)



Sales Volume (MT)



Organic chemicals refers to HMDS, CMIC, Bromobenzene and 2 Bromo whereas Inorganic chemicals refer to Bromides

Export data are inclusive of Deemed Exports

Profit & Loss Statement

| Particulars (Rs. Crs) | Q4 FY25 | Q4 FY24 | Y-o-Y | FY25 | FY24 | Y-o-Y |
|--------------------------------|-------------|-------------|------------|--------------|--------------|-------------|
| Revenue from Operations | 54.9 | 59.6 | -8% | 207.4 | 267.1 | -22% |
| Cost of Goods Sold | 34.0 | 41.3 | | 120.5 | 188.9 | |
| Employee Cost | 5.1 | 4.8 | | 19.5 | 18.0 | |
| Other Expenses | 10.1 | 9.1 | | 34.6 | 33.3 | |
| EBITDA | 5.8 | 4.4 | 32% | 32.9 | 26.9 | 22% |
| Other Income | 3.2 | 3.3 | | 14.3 | 13.2 | |
| Depreciation | 2.7 | 2.5 | | 10.5 | 10.3 | |
| EBIT | 6.2 | 5.2 | | 36.6 | 29.8 | |
| Finance Cost | 0.8 | 1.1 | | 3.5 | 3.5 | |
| Profit before Tax | 5.4 | 4.2 | | 33.1 | 26.3 | |
| Tax | 1.5 | 1.3 | | 8.7 | 7.1 | |
| PAT | 3.9 | 2.9 | 36% | 24.5 | 19.2 | 27% |
| PAT Margin % | 7.2% | 4.9% | | 11.8% | 7.2% | |
| Basic EPS (in Rs.) | 1.08 | 0.79 | | 6.68 | 5.24 | |


Balance Sheet

| ASSETS (Rs. Crs) | Mar-25 | Mar-24 |
|---------------------------------------|--------------|--------------|
| Non-Current Assets | | |
| a) Property, Plant And Equipment | 148.7 | 146.5 |
| b) Capital Work in Progress | 39.9 | 42.4 |
| c) Right Of Use Asset | 0.0 | 0.0 |
| d) Intangible Assets | 0.0 | 0.0 |
| e) Investments | 0.3 | 0.0 |
| f) Other Financial Assets | 42.6 | 0.9 |
| g) Other Non-Current Assets | 3.5 | 2.3 |
| | | |
| Sub-Total - Non-Current Assets | 234.9 | 192.1 |
| | | |
| Current Assets | | |
| a) Inventories | 86.1 | 61.6 |
| b) Financial Assets | | |
| i) Investments | 9.8 | 0.0 |
| ii) Trade Receivables | 51.7 | 81.9 |
| iii) Cash And Cash Equivalent | 7.1 | 7.1 |
| iv) Bank Balances | 134.4 | 163.5 |
| v) Other Financial Assets | 7.1 | 9.6 |
| c) Other Current Assets | 22.6 | 21.8 |
| d) Current tax assets | 0.2 | 7.7 |
| Sub-Total - Current Assets | 319.0 | 353.2 |
| Total - Assets | 553.9 | 545.2 |

| EQUITY AND LIABILITIES ¹⁴ | Mar-25 | Mar-24 |
|--|--------------|--------------|
| EQUITY AND LIABILITIES | | |
| Equity | | |
| a) Equity Share Capital | 36.6 | 36.6 |
| b) Other Equity | 464.0 | 439.8 |
| Total Equity | 500.7 | 476.4 |
| Liabilities | | |
| Non-Current Liabilities | | |
| a) Financial Liabilities | | |
| i) Borrowings | 0.2 | 0.4 |
| ii) Lease Liabilities | 0.0 | 0.0 |
| iii) Other financial liabilities | 0.0 | 0.0 |
| b) Non current Provisions | 0.8 | 0.3 |
| c) Deferred Tax Liabilities (Net) | 4.6 | 4.4 |
| Sub-Total - Non-Current Liabilities | 5.6 | 5.1 |
| Current Liabilities | | |
| a) Financial Liabilities | | |
| i) Borrowing | 24.5 | 42.3 |
| ii) Trade Payables | 16.3 | 12.0 |
| iii) Other Financial Liabilities | 4.2 | 5.5 |
| iv) Lease Liabilities | 0.0 | 0.0 |
| b) Other Current Liabilities | 2.4 | 3.6 |
| c) Short Term Provisions | 0.3 | 0.2 |
| d) Current tax Liabilities | 0.0 | 0.0 |
| Sub-Total - Current Liabilities | 47.7 | 63.7 |
| Total - Equity And Liabilities | 553.9 | 545.2 |

Cash Flow Statement

| Particulars (Rs. Crs.) | Mar-25 | Mar-24 |
|---|--------------|--------------|
| Net Profit Before Tax | 33.1 | 26.3 |
| Adjustments for: Non Cash Items / Other Investment or Financial Items | 0.4 | 1.4 |
| Operating profit before working capital changes | 33.5 | 27.7 |
| Changes in working capital | 9.6 | -6.7 |
| Cash generated from Operations | 43.2 | 21.0 |
| Direct taxes paid (net of refund) | -2.6 | -9.0 |
| Net Cash from Operating Activities | 40.5 | 12.0 |
| Net Cash from Investing Activities | -18.9 | -24.6 |
| Net Cash from Financing Activities | -21.5 | -24.8 |
| Net Decrease in Cash and Cash equivalents | 0.1 | -37.4 |
| Add: Cash & Cash equivalents at the beginning of the period | 7.1 | 44.4 |
| Cash & Cash equivalents at the end of the period | 7.1 | 7.1 |



Company Overview



Company Snapshot

Incorporated in 1988


Manufacturer of Speciality Chemicals

An ISO 9001:2015 and ISO 14001:2015 Certified Company

Business Verticals: Organic Chemicals and Inorganic Chemicals

Manufacturing Facilities near Manjusar, Vadodara, Gujarat

9 Operational Plants, 6 Owned Warehouses



Only Manufacturer of HMDS in India



3rd Largest Manufacturer of HMDS Worldwide



Largest Manufacturer of CMIC worldwide




Only Manufacturer of Zinc Bromide in India



Largest Manufacturer of Calcium Bromide in India

Evolution





Global Presence

FY25 Export
Contribution*:


~37%

Key Countries

- | | |
|------------------------------|------------------------|
| » United States of America | » Japan |
| » Italy | » United Arab Emirates |
| » South Korea | » Russia |
| » Germany | » Spain |
| » People's Republic of China | » Thailand |
| | » Malaysia |

Over Two Decades of Experience in Chemicals

- Manufacturing
- Exports



Well Equipped to Seize Upcoming Opportunities

Key Long-Term Relationships



Organic Chemicals



Inorganic Chemicals



Shree Radha Overseas
CC Gran Limited Liability Company

Longstanding Clients

Strong Base

New Product Development

New Customer Reach

Top 5 customers contribute ~30%

Top 10 customers contribute ~45%


Few customers age more than 2 decades with us

Major customers have been with us for more than 5 years

Well equipped to retain market presence

Leading to increase in new product base and reach out to new customers

Moving up the Value Chain



Key Certifications

Key Certifications



R&D

In-house laboratory to test

- » Raw materials procured
- » New Products & Innovation
- » Final products testing at the various stages of the manufacturing process
- » Well equipped with new instruments & machinery



Environment

Complying All Environment Laws

- » The Environment (Protection) Act, 1986
- » Water Prevention and Control of Pollution Act
- » Air Prevention and Control of Pollution Act, 1981
- » We are a zero-discharge company





Product Overview



Product Portfolio



Organic Chemicals

HMDS

- HMDS, an organosilicon compound, is a reagent and a precursor to bases that are popular in organic synthesis and organometallic chemistry
- HMDS is widely used in the pharmaceutical industry as a silylating agent in the process of manufacture of pharmaceutical drugs of the Penicillin group

CMIC

- CMIC is an antiviral drug intermediate product, which is a key intermediate for anti-AIDS and anti-hepatitis B drug Tenofovir
- The downstream product of CMIC, Tenofovir is a nucleotide antiviral drug developed by Gilead Corporation of the United States.

Bromobenzene

- Bromobenzene, is a clear, colourless or pale-yellow liquid. It is manufactured through bromination of benzene in presence of iron and has form of heavy, mobile, colorless liquid having a pungent odor.

Di-Bromo Methane

- Di-Bromo Methane is a colorless liquid primarily used as a solvent and as an intermediate in the production of various industrial chemicals, including those found in perfumes and pesticides.

Inorganic Chemicals

Bromides

- Oilwell Completion Chemicals are used to complete the well and is normally a salty solution made up of chlorides or bromides
- Company manufacture a range of inorganic bromides, namely: Calcium Bromide (solution and powder), Zinc Bromide (solution) & Sodium Bromide (solution and powder)

Key Products

End User Industry



Pharmaceuticals & Others

Pharmaceuticals

Agrochemicals

Oil Drilling & Fluids

Business Performance (Rs in cr)



Export data are inclusive of Deemed Exports

Manufacturing Facilities



| Sr No | Product categories | Key Products | Installed Capacity (MTPA) |
|-------|---------------------|--|---------------------------|
| 1 | Organic Chemicals | HMDS, CMIC, Bromobenzene, 2 Bromo and other ancillary products | 11,400 |
| 2 | | Proposed P-10 unit | H1FY26e |
| 3 | | Proposed P-11 unit | H1FY26e |
| 4 | Inorganic Chemicals | Range of Inorganic Bromides | 15,000 |

Located at Manjusar near Vadodara, Gujarat

9 Operational Plants

2 Proposed Expansion Plant under process

In-House R&D Laboratory

6 Owned Warehouses

Located at Manjusar near Vadodara, Gujarat



Capacity Expansion

- » We plan to add additional manufacturing capacity P10 unit and P11 unit. These additional capacity will manufacture organic chemicals

Import Substitution

- » Aims to capitalize on the potential growth of Organic Chemicals in India and to substitute imports

Exploring New Applications

- » Plan to expand the new products to have diversified product portfolio with diversified client base

Cost Efficiencies

- » Ongoing improvement in cost-efficiencies in the production process through Process re-engineering for efficient raw material consumption and through economies of scale



Way Forward

Moderate Growth in

Organic Chemicals



Healthy Growth in

Inorganic Chemicals



Exploring
Opportunities in

New Products



Leading to Long Term Sustainable Growth

New Products, New Clients, New Applications, New Opportunities




Financial Highlights




Financial Trends


Total Revenue (Rs. Cr)




EBITDA (Rs. Cr)




PAT (Rs. Cr)




Geographic-Wise (%)



Business-wise (%)



Sales Volume (MT)



Balance Sheet

| ASSETS (Rs. Crs) | Mar-25 | Mar-24 |
|---------------------------------------|--------------|--------------|
| Non-Current Assets | | |
| a) Property, Plant And Equipment | 148.7 | 146.5 |
| b) Capital Work in Progress | 39.9 | 42.4 |
| c) Right Of Use Asset | 0.0 | 0.0 |
| d) Intangible Assets | 0.0 | 0.0 |
| e) Investments | 0.3 | 0.0 |
| f) Other Financial Assets | 42.6 | 0.9 |
| g) Other Non-Current Assets | 3.5 | 2.3 |
| | | |
| Sub-Total - Non-Current Assets | 234.9 | 192.1 |
| | | |
| Current Assets | | |
| a) Inventories | 86.1 | 61.6 |
| b) Financial Assets | | |
| i) Investments | 9.8 | 0.0 |
| ii) Trade Receivables | 51.7 | 81.9 |
| iii) Cash And Cash Equivalent | 7.1 | 7.1 |
| iv) Bank Balances | 134.4 | 163.5 |
| v) Other Financial Assets | 7.1 | 9.6 |
| c) Other Current Assets | 22.6 | 21.8 |
| d) Current tax assets | 0.2 | 7.7 |
| Sub-Total - Current Assets | 319.0 | 353.2 |
| Total - Assets | 553.9 | 545.2 |

| EQUITY AND LIABILITIES ¹⁴ | Mar-25 | Mar-24 |
|--|--------------|--------------|
| EQUITY AND LIABILITIES | | |
| Equity | | |
| a) Equity Share Capital | 36.6 | 36.6 |
| b) Other Equity | 464.0 | 439.8 |
| Total Equity | 500.7 | 476.4 |
| Liabilities | | |
| Non-Current Liabilities | | |
| a) Financial Liabilities | | |
| i) Borrowings | 0.2 | 0.4 |
| ii) Lease Liabilities | 0.0 | 0.0 |
| iii) Other financial liabilities | 0.0 | 0.0 |
| b) Non current Provisions | 0.8 | 0.3 |
| c) Deferred Tax Liabilities (Net) | 4.6 | 4.4 |
| Sub-Total - Non-Current Liabilities | 5.6 | 5.1 |
| Current Liabilities | | |
| a) Financial Liabilities | | |
| i) Borrowing | 24.5 | 42.3 |
| ii) Trade Payables | 16.3 | 12.0 |
| iii) Other Financial Liabilities | 4.2 | 5.5 |
| iv) Lease Liabilities | 0.0 | 0.0 |
| b) Other Current Liabilities | 2.4 | 3.6 |
| c) Short Term Provisions | 0.3 | 0.2 |
| d) Current tax Liabilities | 0.0 | 0.0 |
| Sub-Total - Current Liabilities | 47.7 | 63.7 |
| Total - Equity And Liabilities | 553.9 | 545.2 |

Thank You



Chemcon Speciality Chemicals Ltd.

CIN – L24231GJ1988PLC011652

Mr. Rajesh Gandhi - CFO

Email – rajesh@cscpl.com

www.cscpl.com

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Ms. Shaily Patwa / Mr. Om Kanadia

Email - shaily.p@sgapl.net / om.kanadia@sgapl.net

+91 9819494608 / +91 8454951156

www.sgapl.net

